secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001193125-22-303275
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta reports MGTA-117 Phase 1/2 data: no DLTs, two patients became transplant eligible
--------------------------------------------------------------------------------

- MGTA-117 showed dose-dependent binding and depletion of CD117+ cells; no dose-limiting toxicities observed in 15 patients across Cohorts 1-3.
- Two relapsed/refractory AML/MDS patients became eligible for transplant after a single dose of MGTA-117.
- Phase 1/2 trial currently enrolling Cohort 4 (0.13 mg/kg); aggregate data including Cohort 4 expected Q1 2023.
- Company plans to transition MGTA-117 into transplant-eligible AML/MDS patients in H1 2023 pending regulatory alignment.
- MGTA-145 Phase 2 trial in sickle cell disease data now expected H1 2023 due to enrollment delays.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522303275/0001193125-22-303275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522303275/d434402d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-303275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer